Jasper Therapeutics, Inc.
JSPR
$2.92
-$0.04-1.35%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.88M | 5.65M | 5.51M | 5.43M | 4.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.08M | 21.80M | 25.29M | 19.89M | 15.99M |
| Operating Income | -27.08M | -21.80M | -25.29M | -19.89M | -15.99M |
| Income Before Tax | -26.72M | -21.24M | -24.32M | -18.64M | -14.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.72M | -21.24M | -24.32M | -18.64M | -14.58M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.72M | -21.24M | -24.32M | -18.64M | -14.58M |
| EBIT | -27.08M | -21.80M | -25.29M | -19.89M | -15.99M |
| EBITDA | -26.82M | -21.52M | -25.04M | -19.35M | -15.69M |
| EPS Basic | -1.74 | -1.41 | -1.62 | -1.24 | -0.97 |
| Normalized Basic EPS | -1.09 | -0.88 | -1.01 | -0.78 | -0.61 |
| EPS Diluted | -1.74 | -1.41 | -1.62 | -1.24 | -0.97 |
| Normalized Diluted EPS | -1.09 | -0.88 | -1.01 | -0.78 | -0.61 |
| Average Basic Shares Outstanding | 15.33M | 15.02M | 15.01M | 15.00M | 14.99M |
| Average Diluted Shares Outstanding | 15.33M | 15.02M | 15.01M | 15.00M | 14.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |